Xiao-Tang Kong
Clinical Professor, Neurology
School of Medicine
School of Medicine
M.D., Keck School of Medicine, University of Southern California, 2008
Ph.D., The University of Tokyo, 1996
M.D., Beijing Capital University of Medical Science, 1994
Ph.D., The University of Tokyo, 1996
M.D., Beijing Capital University of Medical Science, 1994
ORCiD: 0000-0001-9487-6975
University of California, Irvine
200 S. Manchester Ave., Suite 206
Mail Code: 4280
Orange, CA 92868
200 S. Manchester Ave., Suite 206
Mail Code: 4280
Orange, CA 92868
Research Interests
Neuro-Oncology, clinical trials, glioblastoma, primary brain tumor, brain cancer, CNS lymphoma, paraneoplastic syndrome, leptomeningeal carcinomatosis, metastatic cancer, spinal cord cancer
Short Biography
Xiao-Tang Kong is a neuro-oncologist and a clinical professor at the University of California (UC) Irvine. She is serving as a Director of Neuro-Oncology Fellowship Program at UC Irvine Health. Her research focuses on new therapeutic modalities for primary and metastatic tumors of the brain and spinal cord. She earned her medical degrees from the Keck School of Medicine at University of Southern California and Capital University of Medical Science in Beijing. She completed her fellowship in Neuro-Oncology at the David Geffen School of Medicine at UCLA. In addition, she earned her PhD in molecular biology of cancer from University of Tokyo.
Publications
Kong XT et al. Phase II study of Bortezomib in combination with Temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiform: Safety and Efficacy Assessment. Int Journal of Radiation Oncology, Biology, Physics., 100 (5): 1195-1203, 2018.
Lu B, Du S, and Kong XT. Immune checkpoint inhibitors for the treatment of glioblastoma. Journal of Solid Tumor. 10 (1): 2020. DOI: 10.5430/jst.v10n1p7 URL: https://doi.org/10.5430/jst.v10n1p7 http://www.sciedu.ca/journal/index.php/jst/article/viewFile/16506/10616
Hrachova M, Nguyen ENT, Fu BD, Dandekar M, Kong, XT et al. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas. Front Neurol. 2020;11:373. Published 2020 May 6. doi:10.3389/fneur.2020.00373
Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umenura Y, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daohistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, et al and Mehta MP. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal Neurooncol (2019) 145: 97. https://doi.org/10.1007/s11060-019-03271-3
Pham JT, Kim RC, Nguyen A, Bota D, Kong XT, Vadera S, Hsu F, Carrillo JA. Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports. CNS Oncology, 7(2): CNS09, 2018
Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncology, 7(3): CNS22, 2018.
Virgil Schijns*, Chrystel Pretto, Anna Strik, Rianne Gloudemans-Rijkers, Laurent Devillers, Denis Pierre, Jinah Chung, Manisha Dandekar, Jose Carrillo, Xiao-Tang Kong, Beverly D. Fu, Frank P.K. Hsu, Florence M. Hofman, Thomas C. Chen, Raphael Zidovetzki, Daniela Bota, Apostolos Stathopoulos. Therapeutic immunization against glioblastoma; the path from preclinical development to clinical application of the therapeutic vaccine Gliovac/ERC1671. International Journal of Molecular Sciences (IJMS), 19(9): 2540-2553, 2018
Tran PN and Kong XT. Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia. Case Rep Neurol., 9(1):114-120, 2017.
Kong XT, Fu D, Carrillo J, and Bota D. Assessing the beneficial impacts of the neuro-oncology hospitalist model: A pilot run at UC Irvine. Neuro Oncology 2016;18 (suppl 6): vi160-vi161.
Kong XT, Alexandru D and Bota D. Epidemiology of Central Nervous System Metastases. In: Brain Metastases from Primary Tumors. Edited by Hayat MA, Elsevier, 2014:11-24.
Clayton E, Madamba J, Kong, XT and Braskett M. Successful desensitization protocol for delayed cutaneuous eruption to temozolomide. The Journal of Allergy and Clinical Immunology: In Practice. 2(3) March/April, 2014 http://dx.doi.org/10.1016/j.jaip.2014.03.016
Lisheng Ge, Neil T. Hoa, Zechariah Wilson, Gabriel Arismendi-Morillo, Xiao-Tang Kong, Rajeev B. Tajhya, Christine Beeton, and Martin R. Jadus. Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. J of International Immunopharmacology. 22 (2): 427-443, 2014
Hardy A, Prins R, Kong XT, Woodworth D, Pope W, Yong W, Cloughesy T, Liau L, and Elingson B. Enhancing tumor response using quatitative volumetry from T1 suntraction maps in malignant glioma treated with dentritic cell vaccination. Neuro Oncology 2014 Nov; 16 (Suppl 5): v 145. doi: 10.1093/neuonc/nou264.30
Xiao-Tang Kong, Stacey Green, Emese Filka, Richard Green, William Yong, Phioanh Nghiemphu, Timothy Cloughesy, Albert Lai. Phase II pilot study of VELCADE® (Bortezomib) in combination with Temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiforme. Neuro-Oncology 15:iii75–iii84, 2013. doi:10.1093/neuonc/not179
Xiao-Tang Kong, Tom Davidson, Albert Lai, Timothy Cloughesy, Phioanh (Leia) Nghiemphu. Long term follow up after the treatment of adult intracranial or intraspinal primary pure germinoma. Neuro-Oncology 15:iii98–iii135, 2013. doi:10.1093/neuonc/not182
Fu DB, Alexandru D, Curticiu D, Kong XT and Bota D. The use of intravitreal rituximab in conjunction with systemic temozolomide and intravenous rituximab for the treatment of primary intraocular lymphoma. Hematology and Leukemia 2013. http://www.hoajonline.com/journals/pdf/2052-434X-1-1.pdf
Beverly Dan Fu, Xiao-Tang Kong and Daniela Bota. A case report of chemotherapy alone for the treatment of primary CNS T-cell lymphoma. Neuro-Oncology 14:vi65–vi85, 2012. doi:10.1093/neuonc/nos229
Kong XT, Gao H and Stanbridge EJ. Mechanism of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function. J Biol Chem. 276(35): 32990-33000, 2001.
Kong XT, Choi SH, Bessho F, Kobayashi M, Hanada R Yamamoto K and Hayashi Y. Codon 201Gly polymorphism type of the DCC gene is related to the disseminated neuroblastoma. Neoplasia, 3(4): 267-272, 2001.
Choi SH, Kong XT, Taki T, Tsuchida Y, Kawaguchi H, Kato H, Hanada R, Look AT and Hayashi Y. Reduced or absent expression and codon 201 polymorphism of DCC gene in rhabdomyosarcoma and Ewing’s sarcoma/PNET family. Int J Mol Med, 6: 463-467, 2000.
Aurelio ON, Kong XT, Gupta S, and Stanbridge EJ. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20(3): 770-778, 2000.
Kong XT, Valentine VA, Rowe ST, Valentine MB, Ragsdale ST, Jones BG, Wilkinson DA, Brodeur GM, Cohn SL and Look AT. Lack of Homozygous inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. Neoplasia, 1(1): 80-89, 1999.
Kong XT, Choi SH, Inoue A, Takita J, Yokota J, Hanada R, Yamamoto K, Bessho F, Yanagisawa M, Hayashi Y. Alterations of the tumour suppressor gene DCC in neuroblastoma. Eur J Cancer, 33(12): 1962-1965, 1997.
Kong XT, Ida K, Ichikawa H, Shimizu K, Ohki M, Maseki N, Kaneko Y, Sako M, Kobayashi Y, Tojou A, Miura I, Kakuda H, Funabiki T, Horibe K, Hamaguchi H, Akiyama Y, Bessho F, Yanagisawa M and Hayashi Y. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood, 90(3): 1192-1199, 1997.
Kong XT, Choi SH, Inoue A, Xu F, Chen T, Takita J, Yokota J, Bessho F, Yanagisawa M, Hanada R, Yamamoto K, and Hayashi Y. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res., 57(17): 3772-3778, 1997.
Kong XT, Choi SH, Takita J, Yokota J, Hanada R, Yamamoto K, Bessho F, Yanagisawa M, Hayashi Y. Alterations of the tumor suppressor gene DCC in Childhood solid tumors. J Jpn Pediatr Society (Japanese), 101: 1492-1498, 1997.
Kong XT, Zhaori GT, Wang GZ and Jiang ZF. Treatment of acute lower respiratory tract infection in children caused by respiratory syncytial virus with inhalation of aerosolized Shuanghuanglian. Chin J Pediatr (Chinese), 34 (1): 11-14, 1996.
Kong XT and Jiang ZF. Current status on ribavirin aerosol treatment of respiratory syncytial virus infection in children in the world (review). Chin J Pediatr (Chinese) 131(2): 119 -121, 1993.
Kong XT, Fang HT, Jiang GQ, Zhai SZ, O' Connell DL and Brewster DR. Treatment of acute bronchiolitis with Chinese herbs. Arch Dis Child (England), 68(4): 468-471, 1993.
Kong XT, Zhaori GT, Wang GZ and Jiang ZF. Inhibition of Shanghuanglian on RSV in vitro and its antiviral mechanism. J Shuanghuanglian (Chinese) 2(1): 1-5, 1992.
Kong XT and Fang HT. Clinical analysis of 110 children with lower respiratory infection due to RSV in Harbin area. J Clin Pediatric (Chinese) 9(5): 299-301, 1991.
Kong XT and Fang HT. Rapid diagnosis of RSV infection by MACEIA. J Harbin Med Univ (Chinese) 23(3): 172-174, 1989.
Lu B, Du S, and Kong XT. Immune checkpoint inhibitors for the treatment of glioblastoma. Journal of Solid Tumor. 10 (1): 2020. DOI: 10.5430/jst.v10n1p7 URL: https://doi.org/10.5430/jst.v10n1p7 http://www.sciedu.ca/journal/index.php/jst/article/viewFile/16506/10616
Hrachova M, Nguyen ENT, Fu BD, Dandekar M, Kong, XT et al. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas. Front Neurol. 2020;11:373. Published 2020 May 6. doi:10.3389/fneur.2020.00373
Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umenura Y, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daohistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, et al and Mehta MP. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal Neurooncol (2019) 145: 97. https://doi.org/10.1007/s11060-019-03271-3
Pham JT, Kim RC, Nguyen A, Bota D, Kong XT, Vadera S, Hsu F, Carrillo JA. Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports. CNS Oncology, 7(2): CNS09, 2018
Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncology, 7(3): CNS22, 2018.
Virgil Schijns*, Chrystel Pretto, Anna Strik, Rianne Gloudemans-Rijkers, Laurent Devillers, Denis Pierre, Jinah Chung, Manisha Dandekar, Jose Carrillo, Xiao-Tang Kong, Beverly D. Fu, Frank P.K. Hsu, Florence M. Hofman, Thomas C. Chen, Raphael Zidovetzki, Daniela Bota, Apostolos Stathopoulos. Therapeutic immunization against glioblastoma; the path from preclinical development to clinical application of the therapeutic vaccine Gliovac/ERC1671. International Journal of Molecular Sciences (IJMS), 19(9): 2540-2553, 2018
Tran PN and Kong XT. Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia. Case Rep Neurol., 9(1):114-120, 2017.
Kong XT, Fu D, Carrillo J, and Bota D. Assessing the beneficial impacts of the neuro-oncology hospitalist model: A pilot run at UC Irvine. Neuro Oncology 2016;18 (suppl 6): vi160-vi161.
Kong XT, Alexandru D and Bota D. Epidemiology of Central Nervous System Metastases. In: Brain Metastases from Primary Tumors. Edited by Hayat MA, Elsevier, 2014:11-24.
Clayton E, Madamba J, Kong, XT and Braskett M. Successful desensitization protocol for delayed cutaneuous eruption to temozolomide. The Journal of Allergy and Clinical Immunology: In Practice. 2(3) March/April, 2014 http://dx.doi.org/10.1016/j.jaip.2014.03.016
Lisheng Ge, Neil T. Hoa, Zechariah Wilson, Gabriel Arismendi-Morillo, Xiao-Tang Kong, Rajeev B. Tajhya, Christine Beeton, and Martin R. Jadus. Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. J of International Immunopharmacology. 22 (2): 427-443, 2014
Hardy A, Prins R, Kong XT, Woodworth D, Pope W, Yong W, Cloughesy T, Liau L, and Elingson B. Enhancing tumor response using quatitative volumetry from T1 suntraction maps in malignant glioma treated with dentritic cell vaccination. Neuro Oncology 2014 Nov; 16 (Suppl 5): v 145. doi: 10.1093/neuonc/nou264.30
Xiao-Tang Kong, Stacey Green, Emese Filka, Richard Green, William Yong, Phioanh Nghiemphu, Timothy Cloughesy, Albert Lai. Phase II pilot study of VELCADE® (Bortezomib) in combination with Temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiforme. Neuro-Oncology 15:iii75–iii84, 2013. doi:10.1093/neuonc/not179
Xiao-Tang Kong, Tom Davidson, Albert Lai, Timothy Cloughesy, Phioanh (Leia) Nghiemphu. Long term follow up after the treatment of adult intracranial or intraspinal primary pure germinoma. Neuro-Oncology 15:iii98–iii135, 2013. doi:10.1093/neuonc/not182
Fu DB, Alexandru D, Curticiu D, Kong XT and Bota D. The use of intravitreal rituximab in conjunction with systemic temozolomide and intravenous rituximab for the treatment of primary intraocular lymphoma. Hematology and Leukemia 2013. http://www.hoajonline.com/journals/pdf/2052-434X-1-1.pdf
Beverly Dan Fu, Xiao-Tang Kong and Daniela Bota. A case report of chemotherapy alone for the treatment of primary CNS T-cell lymphoma. Neuro-Oncology 14:vi65–vi85, 2012. doi:10.1093/neuonc/nos229
Kong XT, Gao H and Stanbridge EJ. Mechanism of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function. J Biol Chem. 276(35): 32990-33000, 2001.
Kong XT, Choi SH, Bessho F, Kobayashi M, Hanada R Yamamoto K and Hayashi Y. Codon 201Gly polymorphism type of the DCC gene is related to the disseminated neuroblastoma. Neoplasia, 3(4): 267-272, 2001.
Choi SH, Kong XT, Taki T, Tsuchida Y, Kawaguchi H, Kato H, Hanada R, Look AT and Hayashi Y. Reduced or absent expression and codon 201 polymorphism of DCC gene in rhabdomyosarcoma and Ewing’s sarcoma/PNET family. Int J Mol Med, 6: 463-467, 2000.
Aurelio ON, Kong XT, Gupta S, and Stanbridge EJ. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20(3): 770-778, 2000.
Kong XT, Valentine VA, Rowe ST, Valentine MB, Ragsdale ST, Jones BG, Wilkinson DA, Brodeur GM, Cohn SL and Look AT. Lack of Homozygous inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. Neoplasia, 1(1): 80-89, 1999.
Kong XT, Choi SH, Inoue A, Takita J, Yokota J, Hanada R, Yamamoto K, Bessho F, Yanagisawa M, Hayashi Y. Alterations of the tumour suppressor gene DCC in neuroblastoma. Eur J Cancer, 33(12): 1962-1965, 1997.
Kong XT, Ida K, Ichikawa H, Shimizu K, Ohki M, Maseki N, Kaneko Y, Sako M, Kobayashi Y, Tojou A, Miura I, Kakuda H, Funabiki T, Horibe K, Hamaguchi H, Akiyama Y, Bessho F, Yanagisawa M and Hayashi Y. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood, 90(3): 1192-1199, 1997.
Kong XT, Choi SH, Inoue A, Xu F, Chen T, Takita J, Yokota J, Bessho F, Yanagisawa M, Hanada R, Yamamoto K, and Hayashi Y. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res., 57(17): 3772-3778, 1997.
Kong XT, Choi SH, Takita J, Yokota J, Hanada R, Yamamoto K, Bessho F, Yanagisawa M, Hayashi Y. Alterations of the tumor suppressor gene DCC in Childhood solid tumors. J Jpn Pediatr Society (Japanese), 101: 1492-1498, 1997.
Kong XT, Zhaori GT, Wang GZ and Jiang ZF. Treatment of acute lower respiratory tract infection in children caused by respiratory syncytial virus with inhalation of aerosolized Shuanghuanglian. Chin J Pediatr (Chinese), 34 (1): 11-14, 1996.
Kong XT and Jiang ZF. Current status on ribavirin aerosol treatment of respiratory syncytial virus infection in children in the world (review). Chin J Pediatr (Chinese) 131(2): 119 -121, 1993.
Kong XT, Fang HT, Jiang GQ, Zhai SZ, O' Connell DL and Brewster DR. Treatment of acute bronchiolitis with Chinese herbs. Arch Dis Child (England), 68(4): 468-471, 1993.
Kong XT, Zhaori GT, Wang GZ and Jiang ZF. Inhibition of Shanghuanglian on RSV in vitro and its antiviral mechanism. J Shuanghuanglian (Chinese) 2(1): 1-5, 1992.
Kong XT and Fang HT. Clinical analysis of 110 children with lower respiratory infection due to RSV in Harbin area. J Clin Pediatric (Chinese) 9(5): 299-301, 1991.
Kong XT and Fang HT. Rapid diagnosis of RSV infection by MACEIA. J Harbin Med Univ (Chinese) 23(3): 172-174, 1989.
Professional Societies
American Academy of Neurology
Society of Neuro-Oncology
Chinese American Neurological Association
Other Experience
Postdoctoral Researcher
UC Irvine, Microbiology and Molecular Genetics 1998—2001
UC Irvine, Microbiology and Molecular Genetics 1998—2001
Postdoctoral Researcher
St. Jude Children's Research Hospital 1997—1998
St. Jude Children's Research Hospital 1997—1998
Link to this profile
https://faculty.uci.edu/profile/?facultyId=6303
https://faculty.uci.edu/profile/?facultyId=6303
Last updated
10/28/2023
10/28/2023